Actively Recruiting
Unraveling the Pathogenesis of Influenza-associated Aspergillosis: a Single-center, Prospective Cohort Pilot Study
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2025-11-17
45
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to study the immune and pathological features of patients with severe community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU), comparing those with influenza infection to those without. The study also seeks to link these findings to the occurrence of secondary invasive pulmonary aspergillosis, a serious lung infection. Participants include adults aged 18 or older admitted to the ICU with respiratory distress caused by either influenza-positive or influenza-negative CAP. Patients are grouped into two categories: those with microbiologically confirmed influenza-related CAP and those with CAP but no influenza infection. The study will observe and compare immune cell profiles, cytokine responses, and neutrophil function in both blood and bronchoalveolar lavage (BAL) fluid samples from these patients. The research will continue through three influenza seasons, spanning approximately three years. Participants will undergo assessments of blood and BAL fluid to analyze immune responses and pathological markers related to their lung condition. The study will track changes over time and correlate them with the development of invasive pulmonary aspergillosis and patient outcomes. This observational study involves no investigational treatments but focuses on detailed monitoring and data collection during the ICU stay and follow-up periods.
CONDITIONS
Brief Title
Influenza Associated Aspergillosis In-depth Investigation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years admitted to ICU with respiratory distress and confirmed influenza diagnosis (for influenza group)
- Patients older than 18 years admitted to ICU with respiratory distress due to community-acquired pneumonia and confirmed absence of influenza (for control group)
You will not qualify if you...
- Age under 18 years
- Pregnant women
- No informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Patients admitted to ICU with respiratory distress are assessed for influenza status and pneumonia diagnosis.
Duration - During ICU stay
Participants undergo immunological and pathological assessments to study differences between influenza and non-influenza pneumonia patients.
Assessments coincide with ICU admission and clinical care; specific timing depends on patient condition.
Duration - Up to 3 years
Participants are monitored over up to 3 influenza seasons to observe immune cell profiles, cytokine production, and pathological changes.
Follow-up data collection occurs throughout study completion period.
Trial Site Locations
Total: 1 location
1
Universitaire Ziekenhuizen Leuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
J
Joost Wauters, PhD
L
Lore Vanderbeke, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here